knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 22:10:32 - browse：827

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Unique patient identifier: Experts argue the benefits, pitfalls

WSS

Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert

Problems with a popular proposal to regulate AI in health care

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

A single Democrat is willing to weaken Medicare negotiation power

Updated Covid vaccine has 54% effectiveness, new study suggests

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

ChatGPT in medicine: STAT answers readers' burning questions

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Tori Bowie and the unacceptable rates of Black maternal death

Why Novartis is going to walk from its acquisition of MorphoSys

Psychedelics group wrestles with new pharma identity

Parkland mass shooting to be reenacted for lawsuit

Moonlake's readout produced a cash windfall. Risks remain

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Peter Hotez and the public health issue of online harassment

Rock icon Freddie Mercury pre

leisure time

Adopting new red light myopia treatments may be short

Eat, drink, but be wary — 4 foods that interact with medications

Gene therapy for Afghan refugees’ infant will be fully covered

Pediatricians' group reaffirms support for gender

Surgery pushed Ben Carson to fame

Russian court extends detention of American musician

explore

focus

leisure time

knowledge